Sensor technology company Opteev Technologies Inc revealed on Thursday that its ViraWarn COVID-19 detection device showed near 100% efficacy at instantly detecting COVID-19 in the air as well as the Omicron and all COVID-19 variants.
The company's data were provided by the National Institutes of Health (NIH) supported laboratory.
On 5 January 2022, the company will announce its full line of ViraWarn detection products at CES 2022 in Las Vegas. The products will include personal diagnostic breath analysis devices as well as room monitoring devices to ebb the flow of the pandemic.
In addition, the NIH-supported lab's certificate of testing and summary of findings will be posted on Opteev's website: www.virawarn.com.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon